SBMJF.US Dimerix Ltd

Healthcare Biotechnology USA Stocks
0.3500 USD
Close of Nov 17, 2026
0.3500 0.3500
Market cap
USD 210M
P/E
-
P/B
24.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is SBMJF.US undervalued?

Graham number

The Graham number of Dimerix Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dimerix Ltd fundamental analysis

No fundamental analysis for Dimerix Ltd yet.

Dimerix Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dimerix Ltd

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

Full company profile